Αποτελέσματα Αναζήτησης
1 Φεβ 2011 · These guidelines provide evidence-based recommendations for the management of various MRSA infections, such as skin and soft tissue, bacteremia, pneumonia, and CNS infections. They also address vancomycin dosing, resistance, and treatment failures.
15 Αυγ 2011 · The Infectious Diseases Society of America (IDSA) provides evidence-based recommendations on the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The guidelines cover skin and soft-tissue infections, bacteremia, pneumonia, and other syndromes, as well as vancomycin use and decolonization.
1 Φεβ 2011 · Evidence-based recommendations for the management of patients with MRSA infections, including skin and soft tissue infections, bacteremia, pneumonia, and others. Covers vancomycin dosing, monitoring, and alternatives, as well as research gaps and areas of controversy.
2 Απρ 2023 · The selection of empiric antibiotic therapy for the treatment of MRSA infection depends on the type of disease, local S. aureus resistance patterns, availability of the drug, side effect profile, and individual patient profile.
3 Φεβ 2021 · These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA.
29 Νοε 2023 · According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), S. aureus with oxacillin MIC values >2 mg/L are mostly methicillin resistant [2]. Issues related to treatment of skin and soft tissue infections in adults caused by MRSA will be reviewed here.
28 Φεβ 2006 · These evidence-based guidelines have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA) infection. The guidelines were further informed by antibiotic susceptibility data on MRSA from the UK.
